Durvalumab vs Empagliflozin

Durvalumab vs Empagliflozin: Overview

This comparison examines the pharmacological differences between Durvalumab and Empagliflozin.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Empagliflozin — 12.4 hours.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7.

Molecular Weight: Empagliflozin — 450.9100 g/mol.

Type: Durvalumab — Antibody; Empagliflozin — Small molecule.